微芯生物(688321.SH):將西格列他鈉中國大陸指定區域市場推廣權益獨家許可給海正藥業
格隆匯12月16日丨微芯生物(688321.SH)宣佈,2020年12月14日,公司第一屆董事會第二十次會議審議通過了《關於簽訂獨佔許可及聯合營銷戰略合作協議的議案》,同意公司及其全資子公司成都微芯與海正藥業(600267.SH)簽署西格列他鈉片(雙洛平®)藥品的《獨佔許可及聯合營銷戰略合作協議》,公司將中國大陸地區內的指定授權區域的市場推廣權益獨家許可給海正藥業,海正藥業據此向公司支付合計1億元人民幣的獨家授權費用。
協議合作期內,從公司產品實現第一次商業銷售之日起計算,當海正藥業的市場推廣銷售金額累計達到合同規定的銷售額時,即觸發相應里程碑事件,海正藥業將按合同規定向公司支付里程碑費用,該費用最高不超過1.2億元人民幣。
另外,協議合作期內,從公司產品實現第一次商業銷售之日起計算,根據海正藥業在授權區域內進行市場推廣達到的銷售額,公司將根據銷售額梯度向海正藥業支付銷售額的48%-55%的市場推廣服務費。
此次戰略營銷合作,有利於公司產品西格列他鈉上市後的市場推廣和銷售,儘快為2型糖尿病患者提供創新治療機制的藥物,為患者提供更多獲益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.